Challenges in interpreting survival metrics in clinical trials: the utility of restricted mean survival analyses
{{output}}
A 75-year-old man enters your clinic with a new diagnosis of high-risk localized prostate cancer. You suggest to him a state-of-the-art treatment plan: radiotherapy to the prostate and lymph nodes, and hormonal therapy. The man expresses a concern about urinar... ...
